EUVIMEDEUVIMED entdecken
Crossref

Neuroblastoma in adolescents and adults: The Memorial Sloan‐Kettering experience

Brian H Kushner, Kim Kramer, Michael P LaQuaglia, Shakeel Modak, Nai-Kong V Cheung

Medical and Pediatric Oncology · 2003-12 · 41 (6) · 508-515

DOI: 10.1002/mpo.10273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical and Pediatric Oncology, online erschienen am 24.10.2003. Verfasst von Brian H Kushner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. kushnerb@mskcc.org. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We reviewed the utility of different treatment modalities in a large series of adolescents/adults with neuroblastoma (NB). Procedure The 30 adolescents/adults (median age, 19 years) had stage 2B (n = 1), 3 (n = 2), or 4 (n = 27) NB. Treatments included conventional and myeloablative therapy; local radiotherapy (RT); immunotherapy with anti‐G D2 3F8 monoclonal antibody ± granulocyte–macrophage colony‐stimulating factor (GM‐CSF); and 3F8 alternating with low‐dose oral etoposide.

Results

Seven patients are in first (n = 4) or second (n = 3) complete/very good partial remission (CR/VGPR) at 9+ to 181+ (median, 45+) months. Among 13 newly diagnosed or minimally prior‐treated patients, no major responses were seen in 4/4 treated with N4/N5 chemotherapy, but 6/9 treated with the higher dose N6/N7 regimens and surgery had major responses, and immunotherapy produced CR in BM in three patients. Among 17 patients referred because of resistant NB, favorable responses occurred in 6/12 treated with high‐dose cyclophosphamide‐based salvage therapy, including one patient who is in CR 170+ months after myeloablative consolidation and five patients who achieved CR/VGPR after 3F8/GM‐CSF (n = 4) or 3F8/oral etoposide (n = 1). With a median follow‐up of 32+ months post‐RT, no local relapses occurred in 10/10 patients who received hyperfractionated 21 Gy RT to prevent regrowth of soft tissue masses that had been resected.

Conclusions

High‐dose chemotherapy and surgery can achieve a minimal disease state in >50% of newly diagnosed older NB patients. In that setting, local RT, and the use of agents with recently confirmed anti‐NB activity, including anti‐G D2 antibodies, and cis ‐retinoic acid, may improve the poor prognosis of these patients reported to date. Med Pediatr Oncol 2003;41:508–515. © 2003 Wiley‐Liss, Inc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChildCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunotherapyMaleNeuroblastomaPrognosisSalvage TherapyTreatment Outcome

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. kushnerb@mskcc.org

Förderung

  • NCI NIH HHS

Zitieren

APA

Kushner, B. H., Kramer, K., LaQuaglia, M. P., Modak, S., & Cheung, N. K. (2003). Neuroblastoma in adolescents and adults: The Memorial Sloan‐Kettering experience. Medical and Pediatric Oncology, 41(6), 508-515. https://doi.org/10.1002/mpo.10273

Vancouver

Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Neuroblastoma in adolescents and adults: The Memorial Sloan‐Kettering experience. Medical and Pediatric Oncology. 2003;41(6):508-515. doi:10.1002/mpo.10273

BibTeX
@article{Kushner2003,
  author = {Kushner, Brian H and Kramer, Kim and LaQuaglia, Michael P and Modak, Shakeel and Cheung, Nai-Kong V},
  title = {Neuroblastoma in adolescents and adults: The Memorial Sloan‐Kettering experience},
  journal = {Medical and Pediatric Oncology},
  year = {2003},
  volume = {41},
  number = {6},
  pages = {508--515},
  doi = {10.1002/mpo.10273}
}
Kostenlos starten →